The Usual Suspects
During the past three months, biotech index SPBIO, has been oscillating, coiling like a spring; preparing for a dramatic move.
Then yesterday (Thursday), there’s an upside launch.
We now have price action instability; either the bulls or the bears are in control.
At this point, we don’t know who has the upper hand.
However, based on the list of recent news items below, it does not look good for the bulls.
Within the past few days, we have this:
Deadline Passes For Pfizer To Submit Results Of Post-Vaccination Heart Inflammation Study To US Regulators
FDA Deviated From Normal Process In Pfizer Vaccine Approval, Documents Show
Former Employees Sue ESPN After Being Fired For COVID Vaccine Refusal
Lead Author Of Research On Pfizer And Moderna Trials Warns COVID Vaccinations Must Be Stopped
Pentagon Drops COVID-19 Vaccine Mandate For Troops
Let’s see if the market’s ready to hand it to this sector. What’s the price action telling us.
Biotech SPBIO, Weekly
The weekly chart shows the potetial breakout.
However, since we’re looking at this from a ‘going short’ perspective (not advice, not a recommendation), the chart following this one is inverted.
When we invert the chart, it takes on a whole different look.
Biotech SPBIO, Weekly (Inverted)
If price action’s spent over three months getting where support has been penetrated only to have it fail into a reversal, the ensuing move has massive potential.
In Wyckoff terms, it’s cause and effect.
The ’cause’ has been three months of congestion. The ‘effect’ is a potential long duration, or wide volatility move.
Before The Open
It’s twenty minutes before the open and 3X leveraged inverse fund LABD, is trading higher by about +3.5%.
This is normal behavior whether we have a reversal or not.
One last check of ZeroHedge, before releasing this post turns up this:
Senator Questions CDC On Why It Claimed No ‘Unexpected Safety Signals’ For COVID Vaccines
The ‘monster’ continues to grow.
Charts by StockCharts
Note: Posts on this site are for education purposes only. They provide one firm’s insight on the markets. Not investment advice. See additional disclaimer here.
The Danger Point®, trade mark: No. 6,505,279